Lili Zheng1, Jing Huang1, Hongfang Kong1, Fang Wang1, Yuan Su1, Hong Xin2. 1. Department of Obstetrics, The Second Hospital of Hebei Medical University, No. 215 Heping Xi Road, Shijiazhuang 050000, Hebei, China. 2. Department of Obstetrics, The Second Hospital of Hebei Medical University, No. 215 Heping Xi Road, Shijiazhuang 050000, Hebei, China. Electronic address: xh_hbyd@163.com.
Abstract
BACKGROUND: Pre-eclampsia is a serious hypertension disease that occurs during pregnancy. Folic acid (FA) supplementation has been reported to reduce pre-eclampsia risk in pregnant women. Here, we aimed to assess whether treatment of high doses of FA in pregnant women with high pre-eclampsia risk could prevent the onset of pre-eclampsia. METHODS: We conducted a randomized clinical trial in 1576 women who had pre-eclampsia or eclampsia in their last pregnancy and had a pregnancy plan. Subjects were randomized into two groups. The low dose (LD) group (n = 788) received 0.4 mg of FA daily from the first 3 months of pregnancy until the entire pregnancy, and the high dose (HD) group (n = 788) received 4 mg of FA per day. We followed up the subjects until production. RESULTS: The plasma homocysteine (homocysteine) and FA levels were significantly higher in the HD group that in the LD group. Severe gestational hypertension, early onset pre-eclampsia (<32 weeks' gestation), severe pre-eclampsia, and newborns' Apgar score <7 at 5 min were remarkably decreased in the HD group compared with the LD group. Further, the incidence of pre-eclampsia was reduced in the HD group with compliance >50%. CONCLUSION: This study has provided evidence that a high dosage of FA supplement from 3 months before pregnancy until the entire pregnancy reduces the recurrent pre-eclampsia.
RCT Entities:
BACKGROUND: Pre-eclampsia is a serious hypertension disease that occurs during pregnancy. Folic acid (FA) supplementation has been reported to reduce pre-eclampsia risk in pregnant women. Here, we aimed to assess whether treatment of high doses of FA in pregnant women with high pre-eclampsia risk could prevent the onset of pre-eclampsia. METHODS: We conducted a randomized clinical trial in 1576 women who had pre-eclampsia or eclampsia in their last pregnancy and had a pregnancy plan. Subjects were randomized into two groups. The low dose (LD) group (n = 788) received 0.4 mg of FA daily from the first 3 months of pregnancy until the entire pregnancy, and the high dose (HD) group (n = 788) received 4 mg of FA per day. We followed up the subjects until production. RESULTS: The plasma homocysteine (homocysteine) and FA levels were significantly higher in the HD group that in the LD group. Severe gestational hypertension, early onset pre-eclampsia (<32 weeks' gestation), severe pre-eclampsia, and newborns' Apgar score <7 at 5 min were remarkably decreased in the HD group compared with the LD group. Further, the incidence of pre-eclampsia was reduced in the HD group with compliance >50%. CONCLUSION: This study has provided evidence that a high dosage of FA supplement from 3 months before pregnancy until the entire pregnancy reduces the recurrent pre-eclampsia.
Authors: Filomena Gomes; Per Ashorn; Sufia Askari; Jose M Belizan; Erick Boy; Gabriela Cormick; Katherine L Dickin; Amalia R Driller-Colangelo; Wafaie Fawzi; G Justus Hofmeyr; Jean Humphrey; Anuradha Khadilkar; Rubina Mandlik; Lynnette M Neufeld; Cristina Palacios; Daniel E Roth; Julie Shlisky; Christopher R Sudfeld; Connie Weaver; Megan W Bourassa Journal: Ann N Y Acad Sci Date: 2022-01-08 Impact factor: 6.499